RxDoctor Payments Data

Ma Clarisse Santos, MD

Nephrology · Honolulu, HINPI 1770896599

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.4% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AstraZeneca accounts for 75.0% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $248 and has fallen 91.9% since, to $20 in 2025. That places this record below the midpoint for nephrology clinicians in HI, where the typical reported total is $2,126.

$510in general payments, 2019–2025

Across 24 payments — averaging $21.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$383
  • Vifor Pharma, Inc.$84
  • Ardelyx, Inc.$21
  • Bayer$19
  • Travere Therapeutics, Inc.$3

What the payments were for

  • Food & beverage$50799%
  • Education$31%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$510 in reported general payments places this provider in the 25th percentile of 57 nephrology providers in Hawaii.

See all nephrology providers in Hawaii

Medicare billing

Part B allowed, 2024
$176,743
Medicare patients
307
Services billed
1,237

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide59$272,539
KerendiaFinerenone107$161,993
FarxigaDapagliflozin Propanediol113$154,463
VeltassaPatiromer Calcium Sorbitex86$135,668
LokelmaSodium Zirconium Cyclosilicate44$68,422
JardianceEmpagliflozin30$46,498
Sevelamer Carbonate102$28,460
Losartan Potassium285$4,417
Calcium Acetate33$2,361
Amlodipine Besylate222$2,356
Allopurinol187$2,351
Olmesartan Medoxomil19$1,980
Carvedilol151$1,582
Calcitriol76$1,197
Furosemide151$1,185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$383$222,885157 claims
BayerKerendia$19$161,993107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 57 nephrology providers in Hawaii.

Other nephrology in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →